Physician profile
Catherine Wang
NPI 1306837562
$6,921.01
in general payments reported to CMS, 2019-2025
20 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,168 · 2020: $285 · 2021: $357 · 2022: $729 · 2023: $1,356 · 2024: $971 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,364 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,363.68 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,770.83 | 2019-2021 | |
| Abbvie INC. | $1,354.67 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Alcon Vision LLC | $1,265.22 | 2019-2025 | Clareon, Rocklatan, Rhopressa |
| Sun Pharmaceutical Industries INC. | $470.31 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $299.21 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $294.05 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Glaukos Corporation | $266.71 | 2022-2025 | Idose, Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Oyster Point Pharma, INC. | $244.73 | 2022-2025 | Tyrvaya, Ryzumvi |
| Rxsight INC | $214.54 | 2022-2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Johnson & Johnson Surgical Vision, INC. | $180.82 | 2019-2023 | Tecnis Iol, Tecnis Iol |
| Rayner Intraocular Lenses Limited | $113.07 | 2023-2025 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Dompe US, INC. | $112.78 | 2024-2025 | Oxervate |
| Harrow Eye, LLC | $74.76 | 2025 | Vevye |
| Ivantis, INC | $73.77 | 2019 | |
| Aerie Pharmaceuticals, INC. | $39.28 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $36.00 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $32.30 | 2025 | Acthar |
| Carl Zeiss Meditec, INC. | $31.60 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $28.72 | 2024 | Xdemvy |
| Smith+Nephew, INC. | $17.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.